-
Listing
Strengthening Europe’s strategic autonomy through capital marketsCzechoslovak Group lists on EuronextLeggi tuttoWorld’s largest defence IPO ever recorded.
Learn more about Euronext’s initiatives to enhance financing and visibility for European aerospace and defence companies -
Informazioni sul trading
Where European Government Bonds meet the futureFixed Income derivativesLeggi tuttoTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLeggi tuttoEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLeggi tuttoEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Leggi tuttoThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLeggi tuttoThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Leggi tuttoShaping capital markets for future generations
GeNeuro lists on Euronext Paris
15/04/2016
Jesús Martin-Garcia, Chairman and CEO of GeNeuro, rings the opening bell, while the company celebrates its listing on Euronext Paris.
GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis and other diseases associated with human endogenous retroviruses (HERV). GeNeuro seeks to block a suspected source of the inflammatory and neurodegenerative components of the disease, rather than targeting the immune response of the body as do most current treatments.